X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare PLETHICO PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

PLETHICO PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    PLETHICO PHARMA DIVIS LABORATORIES PLETHICO PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x -1.1 33.3 - View Chart
P/BV x 0.0 5.4 0.3% View Chart
Dividend Yield % 0.0 0.9 -  

Financials

 PLETHICO PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    PLETHICO PHARMA
Mar-14
DIVIS LABORATORIES
Mar-17
PLETHICO PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs3951,222 32.3%   
Low Rs31784 4.0%   
Sales per share (Unadj.) Rs604.4153.1 394.8%  
Earnings per share (Unadj.) Rs32.539.9 81.3%  
Cash flow per share (Unadj.) Rs51.344.6 115.1%  
Dividends per share (Unadj.) Rs010.00 0.0%  
Dividend yield (eoy) %01.0 0.0%  
Book value per share (Unadj.) Rs473.6201.8 234.7%  
Shares outstanding (eoy) m34.08265.47 12.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x0.46.6 5.4%   
Avg P/E ratio x6.625.1 26.1%  
P/CF ratio (eoy) x4.222.5 18.5%  
Price / Book Value ratio x0.55.0 9.1%  
Dividend payout %025.0 0.0%   
Avg Mkt Cap Rs m7,262266,266 2.7%   
No. of employees `000NA9.7 0.0%   
Total wages/salary Rs m1,5964,687 34.0%   
Avg. sales/employee Rs ThNM4,175.0-  
Avg. wages/employee Rs ThNM481.5-  
Avg. net profit/employee Rs ThNM1,089.3-  
INCOME DATA
Net Sales Rs m20,59840,643 50.7%  
Other income Rs m386749 51.6%   
Total revenues Rs m20,98441,392 50.7%   
Gross profit Rs m2,81814,460 19.5%  
Depreciation Rs m6421,233 52.1%   
Interest Rs m1,59323 7,049.6%   
Profit before tax Rs m96913,953 6.9%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m-1383,349 -4.1%   
Profit after tax Rs m1,10710,604 10.4%  
Gross profit margin %13.735.6 38.4%  
Effective tax rate %-14.324.0 -59.5%   
Net profit margin %5.426.1 20.6%  
BALANCE SHEET DATA
Current assets Rs m18,87740,105 47.1%   
Current liabilities Rs m11,8966,595 180.4%   
Net working cap to sales %33.982.5 41.1%  
Current ratio x1.66.1 26.1%  
Inventory Days Days36119 30.3%  
Debtors Days Days19881 245.2%  
Net fixed assets Rs m9,86119,995 49.3%   
Share capital Rs m341531 64.2%   
"Free" reserves Rs m12,33153,043 23.2%   
Net worth Rs m16,13953,574 30.1%   
Long term debt Rs m4,7060-   
Total assets Rs m33,14661,585 53.8%  
Interest coverage x1.6618.4 0.3%   
Debt to equity ratio x0.30-  
Sales to assets ratio x0.60.7 94.2%   
Return on assets %8.117.3 47.2%  
Return on equity %6.919.8 34.7%  
Return on capital %12.326.1 47.1%  
Exports to sales %21.40-   
Imports to sales %15.225.2 60.3%   
Exports (fob) Rs m4,402NA-   
Imports (cif) Rs m3,13610,259 30.6%   
Fx inflow Rs m4,40235,384 12.4%   
Fx outflow Rs m3,18410,399 30.6%   
Net fx Rs m1,21924,985 4.9%   
CASH FLOW
From Operations Rs m2,43711,493 21.2%  
From Investments Rs m-6,265-11,372 55.1%  
From Financial Activity Rs m2,490-93 -2,674.7%  
Net Cashflow Rs m-1,33728 -4,708.3%  

Share Holding

Indian Promoters % 82.7 52.0 159.0%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 4.3 11.8 36.4%  
FIIs % 5.5 19.0 28.9%  
ADR/GDR % 0.0 0.0 -  
Free float % 7.5 17.2 43.6%  
Shareholders   10,665 31,796 33.5%  
Pledged promoter(s) holding % 85.7 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare PLETHICO PHARMA With:   PANACEA BIOTECH  BIOCON LTD  UNICHEM LAB  NATCO PHARMA  ELDER PHARMA  

Compare PLETHICO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Share Markets Extend Gains; Energy & PSU Stocks Rally(12:30 pm)

Stock markets in India continue to trade higher taking cues from their key Asian counterparts. Sectoral indices are trading in green with stocks in the oil & gas sector.

Related Views on News

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

More Views on News

Most Popular

My Top Five Stocks After the Karnataka Elections(The 5 Minute Wrapup)

May 16, 2018

The markets seem confused. They're neither going up nor down. What should investors do? Consider Safe Stocks. Here's the top 5 Safe Stocks in the market today.

How A Storm Destroyed Rain Industries... And a Superb Small Cap Stock I Recommend(Profit Hunter)

May 17, 2018

A mutual fund regulation could cause small cap prices to tank - If you haven't been paying attention to your small caps - now is the time to catch the opportunities that start pouring in.

Has the Indian Home Buyer Become Smarter?(Vivek Kaul's Diary)

May 17, 2018

Home loans continue to grow, despite falling sales. What explains this phenomenon?

Beware the 5th year of the Modi Regime(The Honest Truth)

May 22, 2018

2017 was a great year for the market. You were rewarded for taking excessive risk. But Ajit Dayal believes 2018 will be different. You will be rewarded for doing the opposite. Read on to know more...

Beware of Inflated Stock Market Angels(Sector Info)

May 17, 2018

The stock of Vakrangee helps us understand why it's a bad idea to chase high-flying stocks.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

PLETHICO PHARMA SHARE PRICE


Jun 13, 2016 (Close)

TRACK PLETHICO PHARMA

  • Track your investment in PLETHICO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON PLETHICO PHARMA

PLETHICO PHARMA 5-YR ANALYSIS

COMPARE PLETHICO PHARMA WITH

MARKET STATS